BSX PE Ratio & Valuation,Is BSX Overvalued

BSX Relative Valuation

BSX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BSX is overvalued; if below, it's undervalued.

Historical Valuation

Boston Scientific Corp (BSX) is now in the Fair zone, suggesting that its current forward PE ratio of 27.91 is considered Fairly compared with the five-year average of 27.08. The fair price of Boston Scientific Corp (BSX) is between 83.10 to 106.30 according to relative valuation methord.

Relative Value

Fair Zone

83.10-106.30

Current Price：92.58

Fair

27.91

22.24

EV/EBITDA

Boston Scientific Corp. (BSX) has a current EV/EBITDA of 22.24. The 5-year average EV/EBITDA is 21.43. The thresholds are as follows: Strongly Undervalued below 14.24, Undervalued between 14.24 and 17.84, Fairly Valued between 25.02 and 17.84, Overvalued between 25.02 and 28.61, and Strongly Overvalued above 28.61. The current Forward EV/EBITDA of 22.24 falls within the Historic Trend Line -Fairly Valued range.

24.26

EV/EBIT

Boston Scientific Corp. (BSX) has a current EV/EBIT of 24.26. The 5-year average EV/EBIT is 23.40. The thresholds are as follows: Strongly Undervalued below 16.21, Undervalued between 16.21 and 19.81, Fairly Valued between 26.99 and 19.81, Overvalued between 26.99 and 30.59, and Strongly Overvalued above 30.59. The current Forward EV/EBIT of 24.26 falls within the Historic Trend Line -Fairly Valued range.

6.32

Boston Scientific Corp. (BSX) has a current PS of 6.32. The 5-year average PS is 5.67. The thresholds are as follows: Strongly Undervalued below 3.37, Undervalued between 3.37 and 4.52, Fairly Valued between 6.82 and 4.52, Overvalued between 6.82 and 7.97, and Strongly Overvalued above 7.97. The current Forward PS of 6.32 falls within the Historic Trend Line -Fairly Valued range.

28.13

P/OCF

Boston Scientific Corp. (BSX) has a current P/OCF of 28.13. The 5-year average P/OCF is 28.92. The thresholds are as follows: Strongly Undervalued below 17.17, Undervalued between 17.17 and 23.05, Fairly Valued between 34.80 and 23.05, Overvalued between 34.80 and 40.68, and Strongly Overvalued above 40.68. The current Forward P/OCF of 28.13 falls within the Historic Trend Line -Fairly Valued range.

44.27

P/FCF

Boston Scientific Corp. (BSX) has a current P/FCF of 44.27. The 5-year average P/FCF is 37.37. The thresholds are as follows: Strongly Undervalued below 19.53, Undervalued between 19.53 and 28.45, Fairly Valued between 46.29 and 28.45, Overvalued between 46.29 and 55.21, and Strongly Overvalued above 55.21. The current Forward P/FCF of 44.27 falls within the Historic Trend Line -Fairly Valued range.

Boston Scientific Corp (BSX) has a current Price-to-Book (P/B) ratio of 5.86. Compared to its 3-year average P/B ratio of 5.40 , the current P/B ratio is approximately 8.56% higher. Relative to its 5-year average P/B ratio of 4.67, the current P/B ratio is about 25.49% higher. Boston Scientific Corp (BSX) has a Forward Free Cash Flow (FCF) yield of approximately 2.79%. Compared to its 3-year average FCF yield of 1.78%, the current FCF yield is approximately 56.70% lower. Relative to its 5-year average FCF yield of 1.88% , the current FCF yield is about 48.39% lower.

5.86

P/B

Median3y

5.40

Median5y

4.67

2.79

FCF Yield

Median3y

1.78

Median5y

1.88

Competitors Valuation Multiple

The average P/S ratio for BSX's competitors is 7.24, providing a benchmark for relative valuation. Boston Scientific Corp Corp (BSX) exhibits a P/S ratio of 6.32, which is -12.61% above the industry average. Given its robust revenue growth of 20.34%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of BSX increased by 3.65% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 11.12 to 14.91.

The secondary factor is the Revenue Growth, contributed 20.34%to the performance.

Overall, the performance of BSX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

20.34%

4.21B → 5.07B

Revenue Growth

34.08%

11.12 → 14.91

Margin Expansion

-50.77%

100.54 → 49.50

P/E Change

3.65%

89.32 → 92.58

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Boston Scientific Corp (BSX) currently overvalued or undervalued?

What is Boston Scientific Corp (BSX) fair value?

BSX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Boston Scientific Corp (BSX) is between 83.10 to 106.30 according to relative valuation methord.

How does BSX's valuation metrics compare to the industry average?

What is the current P/B ratio for Boston Scientific Corp (BSX) as of Dec 15 2025?

As of Dec 15 2025, Boston Scientific Corp (BSX) has a P/B ratio of 5.86. This indicates that the market values BSX at 5.86 times its book value.

What is the current FCF Yield for Boston Scientific Corp (BSX) as of Dec 15 2025?

As of Dec 15 2025, Boston Scientific Corp (BSX) has a FCF Yield of 2.79%. This means that for every dollar of Boston Scientific Corp’s market capitalization, the company generates 2.79 cents in free cash flow.

What is the current Forward P/E ratio for Boston Scientific Corp (BSX) as of Dec 15 2025?

As of Dec 15 2025, Boston Scientific Corp (BSX) has a Forward P/E ratio of 27.91. This means the market is willing to pay $27.91 for every dollar of Boston Scientific Corp’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Boston Scientific Corp (BSX) as of Dec 15 2025?

As of Dec 15 2025, Boston Scientific Corp (BSX) has a Forward P/S ratio of 6.32. This means the market is valuing BSX at $6.32 for every dollar of expected revenue over the next 12 months.

BSX Valuation